New Blood: Former Novartis Exec Transitions to Rubius Therapeutics
New Red-Blood-Cell-Derived Therapies Are Poised to Launch Rubius into the Spotlight.
Improving Human Health: The Promise of Epigenetics
A New Perspective for Genomic Research from Prof. Shankar Balsubramanian
Translating Innovation into Therapies
Antimicrobial Resistance and Drug Commercialization Were Key Topics at the Recent ON Helix Conference in Cambridge, U.K.
Literature Review: Dielectrophoresis to the Fore
Old Methodology Resurrected to Allow Inexpensive Label-Free Separation of Cell Populations
- Soluble Therapeutics
- 1500 1st Avenue North L113
- Birmingham AL, 35203
- UNITED STATES
Soluble Therapeutics commercialized the HSC™ Technology, a platform for optimizing protein formulations that can increase the solubility and stability of proteins for use as therapeutics, vaccines, diagnostics, and research reagents. The HSC Technology combines high-throughput self-interaction chromatography with a predictive algorithm to compress the amount of time it takes to derive optimal formulations for the protein in question. The HSC Technology is available on a fee-for-service basis, or companies can purchase the HSC instrument for use in their own laboratories.